The Department of Neurology runs a large number of clinical trials in nearly every subspecialty of neurology. Below is a list of the department’s current clinical trials.
About participating
What is a clinical trial?
Clinical trials are carefully designed research studies involving human participants. Their purpose is to discover the most effective ways to treat, diagnose or prevent diseases. The insights gained from these trials help improve medical care for future patients.
To ensure safety, clinical studies follow strict ethical guidelines and are often regulated by federal agencies. These safeguards are in place to protect participants from unnecessary side effects and other risks.
Active clinical trials
- Conditions: Amyloidosis; Amyloid Cardiomyopathy; Transthyretin Amyloidosis; Cardiomyopathies; Heart Diseases; Polyneuropathies Interventions: Drug: Acoramidis; Drug: Placebo oral tablet Sponsors: Eidos Therapeutics, a BridgeBio company Recruiting
- Conditions: Tauopathies Interventions: Drug: 18F-JSS20-183A PET; Diagnostic Test: Brain MRI; Diagnostic Test: Amyloid PET; Behavioral: Neurological Assessments Sponsors: University of Pennsylvania Recruiting
- Conditions: Alzheimer Disease; Cognitive Dysfunction; Dementia Interventions: Drug: JNJ-63733657; Drug: Placebo Sponsors: Janssen Research & Development, LLC Active, not recruiting
- Conditions: Alzheimers Disease; Dementia; Alzheimers Disease, Familial Interventions: Drug: E2814; Drug: Lecanemab; Drug: Matching Placebo (E2814) Sponsors: Washington University School of Medicine; Alzheimer's Association; National Institute on Aging (NIA); Accelerating Medicines Partnership (AMP); Eisai Inc. Active, not recruiting
- Conditions: Alzheimers Disease; Dementia; Alzheimers Disease, Familial Interventions: Drug: Remternetug (SC); Drug: Matching Placebo (Remternetug) Sponsors: Washington University School of Medicine; Alzheimer's Association; Eli Lilly and Company; National Institute on Aging (NIA) Recruiting
- Conditions: Alzheimer's Disease; Dementia; Alzheimer's Disease, Familial Interventions: Drug: lecanemab Sponsors: Washington University School of Medicine; Alzheimer's Association; Eisai Inc. Active, not recruiting
- Conditions: Alzheimers Disease; Dementia; Alzheimers Disease, Familial Interventions: Drug: Gantenerumab; Drug: Solanezumab; Drug: Matching Placebo (Gantenerumab); Drug: Matching Placebo (Solanezumab); Drug: Gantenerumab; Drug: E2814; Drug: Lecanemab; Drug: Matching Placebo (E2814) Sponsors: Washington University School of Medicine; Eli Lilly and Company; Hoffmann-La Roche; Alzheimer's Association; National Institute on Aging (NIA); Avid Radiopharmaceuticals; Accelerating Medicines Partnership (AMP); Eisai Inc.; Janssen, LP Active, not recruiting
- Conditions: Alzheimers Disease; Dementia; Alzheimers Disease, Familial Interventions: Drug: Remternetug; Drug: Matching Placebo (Remternetug) Sponsors: Washington University School of Medicine; Alzheimer's Association; Eli Lilly and Company; National Institute on Aging (NIA); GHR Foundation; Private Donors Recruiting
- Conditions: Alzheimer Disease Interventions: Drug: Lemborexant 10 mg; Drug: Lemborexant 20mg; Drug: Placebo Sponsors: Washington University School of Medicine; National Institutes of Health (NIH); Eisai Inc.; National Institute on Aging (NIA) Recruiting
- Conditions: Cognitive Impairment, Mild; Dementia; Cardiovascular Diseases Interventions: Drug: Atorvastatin 40 Mg Oral Tablet; Drug: Placebo oral tablet Sponsors: Duke University; National Institute on Aging (NIA); National Heart, Lung, and Blood Institute (NHLBI); Wake Forest University Health Sciences Recruiting
- Conditions: Frontotemporal Dementia; Frontotemporal Lobar Degeneration; FTD-GRN; FTD; FTLD Sponsors: The Bluefield Project to Cure Frontotemporal Dementia; Mayo Clinic; University of California, San Francisco Active, not recruiting
- Conditions: Alzheimer Disease Interventions: Drug: 18F-Flortaucipir radiopharmaceutical; Drug: 18F-MK-6240 radiopharmaceutical; Drug: Amyloid-β radiopharmaceutical (11C-PiB or 18F-Florbetaben or 18F-NAV-4694 or 18F-Flutemetamol) Sponsors: Tharick Pascoal; National Institute on Aging (NIA) Active, not recruiting
- Conditions: Alzheimer's Disease Sponsors: Washington University School of Medicine; National Institute on Aging (NIA) Recruiting
- Conditions: Chronic Pain; Depression, Anxiety Interventions: Other: Just-In-Time Adaptive Interventions (JITAIs); Behavioral: Wysa for Chronic Pain Sponsors: Washington University School of Medicine; National Institute of Mental Health (NIMH); Duke University; Wysa Recruiting
- Conditions: Parkinsons Interventions: Radiation: PiB and VAT Sponsors: Washington University School of Medicine; National Institutes of Health (NIH); National Institute of Neurological Disorders and Stroke (NINDS); National Institute on Aging (NIA) Recruiting
- Conditions: Alzheimer Disease; Dementia of Alzheimer Type Interventions: Other: Arm A , Arm B, Arm C, & Arm D Sponsors: Washington University School of Medicine Active, not recruiting
- Conditions: Alzheimers Disease; Dementia; Alzheimers Disease, Familial Interventions: Drug: Gantenerumab Sponsors: Washington University School of Medicine; Hoffmann-La Roche; Alzheimer's Association; National Institute on Aging (NIA) Terminated
- Conditions: Cognitive Impairment; Dementia Interventions: Other: No interventions Sponsors: Massachusetts General Hospital; Duke University; Johns Hopkins University; University of New Mexico; University of Southern California; University of Kentucky; Rush University Medical Center; University of Maryland, Baltimore; University of California, San Francisco; University of California, Los Angeles; University of California, Davis; University of Texas; The University of Texas Health Science Center at San Antonio; The University of Texas Health Science Center, Houston; Mayo Clinic; University of Mississippi Medical Center; Washington University School of Medicine; Olive View-UCLA Education & Research Institute Active, not recruiting
For a more comprehensive list of our Alzheimer disease clinical trials, please visit the Knight ADRC website, the Knight ADRC Clinical Trials Unit website and DIAN website.
- Conditions: Dravet Syndrome Interventions: Drug: zorevunersen; Other: Sham Comparator Sponsors: Stoke Therapeutics, Inc Recruiting
- Conditions: Tauopathies Interventions: Diagnostic Test: Brain MRI Scan; Behavioral: Neurologic exam Sponsors: University of Pennsylvania Recruiting
- Conditions: Tauopathies Interventions: Drug: 18F-JSS20-183A PET; Diagnostic Test: Brain MRI; Diagnostic Test: Amyloid PET; Behavioral: Neurological Assessments Sponsors: University of Pennsylvania Recruiting
- Conditions: Tourette Syndrome Interventions: Drug: Ecopipam Sponsors: Emalex Biosciences Inc. Active, not recruiting
- Conditions: Tauopathies Interventions: Drug: 11C-M503 PET; Diagnostic Test: Brain MRI; Diagnostic Test: Amyloid PET; Behavioral: Neurological assessments Sponsors: University of Pennsylvania Recruiting
- Conditions: Parkinsons Interventions: Radiation: PiB and VAT Sponsors: Washington University School of Medicine; National Institutes of Health (NIH); National Institute of Neurological Disorders and Stroke (NINDS); National Institute on Aging (NIA) Recruiting
- Conditions: Relapsing Multiple Sclerosis; Relapsing Remitting Multiple Sclerosis; Secondary Progressive Multiple Sclerosis Interventions: Procedure: Autologous Hematopoietic Stem Cell Transplantation; Biological: Best Available Therapy (BAT) Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); Immune Tolerance Network (ITN); Blood and Marrow Transplant Clinical Trials Network; PPD Development, LP; Rho Federal Systems Division, Inc. Recruiting
- Conditions: Multiple Sclerosis Interventions: Drug: [18F] FZTA Sponsors: Washington University School of Medicine Recruiting
- Conditions: Multiple Sclerosis Interventions: Diagnostic Test: MRI Sponsors: The Cleveland Clinic; National Institute of Neurological Disorders and Stroke (NINDS); University of Pennsylvania; Cedars-Sinai Medical Center; National Institutes of Health (NIH) Active, not recruiting
- Conditions: Multiple Sclerosis Sponsors: Washington University School of Medicine; National Institute of Allergy and Infectious Diseases (NIAID); University of Colorado, Denver; University of Ottawa; Montana State University Completed
- Conditions: Rheumatoid Arthritis (RA); Systemic Lupus Erythematosus (SLE); Pemphigus Vulgaris; Multiple Sclerosis (MS); Systemic Sclerosis (SSc); Pediatric SLE; Juvenile Idiopathic Arthritis (JIA); Juvenile Dermatomyositis (JDM); Pediatric-Onset Multiple Sclerosis (POMS) Interventions: Biological: Moderna mRNA-1273; Biological: BNT162b2; Biological: Ad26.COV2.S; Drug: Continue IS (MMF or MPA); Drug: Continue IS (MTX); Biological: Continue IS (B cell depletion therapy); Biological: Monovalent [B.1.351] CoV2 preS dTM-AS03; Drug: Withhold IS (MMF or MPA); Drug: Withhold IS (MTX); Drug: Withhold IS (B cell depletion therapy); Biological: Moderna mRNA-1273, Bivalent; Biological: BNT162b2, Bivalent Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); Autoimmunity Centers of Excellence; Rho Federal Systems […]
- Conditions: Tuberous Sclerosis; Lymphangioleiomyomatosis Interventions: Procedure: Phlebotomy; Procedure: Buccal (cheek) swab; Genetic: Genetic Testing; Other: Tissue donation after routine clinical procedure Sponsors: National Tuberous Sclerosis Association Recruiting
- Conditions: Multiple Sclerosis; Primary Progressive Multiple Sclerosis (PPMS); Secondary Progressive Multiple Sclerosis (SPMS); Non-Active Secondary Progressive Multiple Sclerosis; Non-Active SPMS; Autoimmune Diseases of the Nervous System; Nervous System Diseases; Autoimmune Diseases; Demyelinating Diseases; Immune System Diseases; Demyelinating Autoimmune Diseases, Central Nervous System (CNS) Interventions: Drug: IDP-023; Drug: Ocrelizumab; Drug: Interleukin-2; Drug: Cyclophosphamide; Drug: Fludarabine; Drug: Mesna Sponsors: Indapta Therapeutics, INC. Suspended
- Conditions: Spinal Cord Injuries; Stroke; Multiple Sclerosis Interventions: Behavioral: Fatigue self-management SMS intervention Sponsors: Washington University School of Medicine; The Foundation for Barnes-Jewish Hospital Completed
- Conditions: Spinal Muscular Atrophy; Spinal Muscular Atrophy Type 3; Spinal Muscular Atrophy Type 2; SMA; Neuromuscular Diseases; Muscular Atrophy; Atrophy; Muscular Atrophy, Spinal; Neuromuscular Manifestations; Anti-myostatin Interventions: Drug: Apitegromab; Drug: Placebo Sponsors: Scholar Rock, Inc. Completed
- Conditions: Amyloidosis; Amyloid Cardiomyopathy; Transthyretin Amyloidosis; Cardiomyopathies; Heart Diseases; Polyneuropathies Interventions: Drug: Acoramidis; Drug: Placebo oral tablet Sponsors: Eidos Therapeutics, a BridgeBio company Recruiting
- Conditions: Muscular Dystrophy, Duchenne Interventions: Genetic: delandistrogene moxeparvovec Sponsors: Sarepta Therapeutics, Inc.; Hoffmann-La Roche Recruiting
- Conditions: Duchenne Muscular Dystrophy Interventions: Genetic: SGT-003 Sponsors: Solid Biosciences Inc. Recruiting
- Conditions: Childhood Cancer Interventions: Other: Highlighting Patients at Risk for Sensory Screening (HPARSS) Sponsors: Washington University School of Medicine; St. Jude Children's Research Hospital Recruiting
- Conditions: Myotonic Dystrophy Type 1 (DM1) Interventions: Drug: VX-670; Drug: Placebo Sponsors: Vertex Pharmaceuticals Incorporated Recruiting
- Conditions: Peripheral Nerve Injury Upper Limb; Peripheral Nerve Injury (PNI) Interventions: Combination Product: NTX-001 (PEG-Fusion) Sponsors: Neuraptive Therapeutics Inc. Recruiting
- Conditions: Duchenne Muscular Dystrophy Interventions: Drug: SRP-4045; Drug: SRP-4053; Drug: Placebo Sponsors: Sarepta Therapeutics, Inc. Completed
- Conditions: Cubital Tunnel Syndrome; Peroneal Nerve Entrapment Interventions: Device: Mechanomyography (MMG) Sponsors: Washington University School of Medicine; Mayo Clinic Completed
- Conditions: Duchenne Muscular Dystrophy Interventions: Genetic: delandistrogene moxeparvovec; Procedure: Plasmapheresis Sponsors: Sarepta Therapeutics, Inc. Terminated
- Conditions: Spinal Muscular Atrophy; Neuromuscular Diseases; SMA Interventions: Drug: taldefgrobep alfa; Drug: Placebo; Drug: taldefgrobep alfa Sponsors: Biohaven Pharmaceuticals, Inc. Active, not recruiting
- Conditions: Rheumatoid Arthritis (RA); Systemic Lupus Erythematosus (SLE); Pemphigus Vulgaris; Multiple Sclerosis (MS); Systemic Sclerosis (SSc); Pediatric SLE; Juvenile Idiopathic Arthritis (JIA); Juvenile Dermatomyositis (JDM); Pediatric-Onset Multiple Sclerosis (POMS) Interventions: Biological: Moderna mRNA-1273; Biological: BNT162b2; Biological: Ad26.COV2.S; Drug: Continue IS (MMF or MPA); Drug: Continue IS (MTX); Biological: Continue IS (B cell depletion therapy); Biological: Monovalent [B.1.351] CoV2 preS dTM-AS03; Drug: Withhold IS (MMF or MPA); Drug: Withhold IS (MTX); Drug: Withhold IS (B cell depletion therapy); Biological: Moderna mRNA-1273, Bivalent; Biological: BNT162b2, Bivalent Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); Autoimmunity Centers of Excellence; Rho Federal Systems […]
- Conditions: Neuropathic Pain Interventions: Drug: Ondansetron 16 mg with Tariquidar; Drug: Ondansetron 16 mg with Placebo Sponsors: Washington University School of Medicine Completed
- Conditions: Duchenne Muscular Dystrophy Interventions: Genetic: delandistrogene moxeparvovec; Genetic: placebo Sponsors: Sarepta Therapeutics, Inc.; Hoffmann-La Roche Active, not recruiting
- Conditions: Duchenne Muscular Dystrophy Interventions: Drug: Givinostat Sponsors: Italfarmaco; Cromsource Active, not recruiting
- Conditions: Sarcoma; Malignant Peripheral Nerve Sheath Tumors Interventions: Drug: PLX3397; Drug: sirolimus Sponsors: Gulam Manji; Daiichi Sankyo Terminated
- Conditions: Spinal Muscular Atrophy (SMA) Interventions: Other: Prospective observational registry; Drug: Zolgensma Sponsors: Novartis Pharmaceuticals Recruiting
An error has occurred, which probably means the feed is down. Try again later.
An error has occurred, which probably means the feed is down. Try again later.
- Conditions: Spinal Muscular Atrophy; Spinal Muscular Atrophy Type 3; Spinal Muscular Atrophy Type 2; SMA; Neuromuscular Diseases; Muscular Atrophy; Atrophy; Muscular Atrophy, Spinal; Neuromuscular Manifestations; Anti-myostatin Interventions: Drug: Apitegromab; Drug: Placebo Sponsors: Scholar Rock, Inc. Completed
- Conditions: Muscular Dystrophy, Duchenne Interventions: Genetic: delandistrogene moxeparvovec Sponsors: Sarepta Therapeutics, Inc.; Hoffmann-La Roche Recruiting
- Conditions: Duchenne Muscular Dystrophy Interventions: Genetic: SGT-003 Sponsors: Solid Biosciences Inc. Recruiting
- Conditions: Pompe Disease Interventions: Drug: S-606001; Drug: Placebo Sponsors: Shionogi Recruiting
- Conditions: Duchenne Muscular Dystrophy Interventions: Drug: SRP-4045; Drug: SRP-4053; Drug: Placebo Sponsors: Sarepta Therapeutics, Inc. Completed
- Conditions: Pompe Disease (Late-onset) Interventions: Biological: Cipaglucosidase Alfa; Drug: Miglustat Sponsors: Amicus Therapeutics Active, not recruiting
- Conditions: Duchenne Muscular Dystrophy Interventions: Genetic: delandistrogene moxeparvovec; Procedure: Plasmapheresis Sponsors: Sarepta Therapeutics, Inc. Terminated
- Conditions: Spinal Muscular Atrophy; Neuromuscular Diseases; SMA Interventions: Drug: taldefgrobep alfa; Drug: Placebo; Drug: taldefgrobep alfa Sponsors: Biohaven Pharmaceuticals, Inc. Active, not recruiting
- Conditions: Duchenne Muscular Dystrophy Interventions: Genetic: delandistrogene moxeparvovec; Genetic: placebo Sponsors: Sarepta Therapeutics, Inc.; Hoffmann-La Roche Active, not recruiting
- Conditions: Duchenne Muscular Dystrophy Interventions: Drug: Givinostat Sponsors: Italfarmaco; Cromsource Active, not recruiting
- Conditions: Spinal Muscular Atrophy (SMA) Interventions: Other: Prospective observational registry; Drug: Zolgensma Sponsors: Novartis Pharmaceuticals Recruiting
- Conditions: Ischemic Stroke; Sleep Apnea; Sleep Apnea, Obstructive; Stroke; CPAP; Telemedicine; Home Sleep Apnea Test; Randomized Clinical Trial; Multicenter Trial Interventions: Device: CPAP Sponsors: University of Michigan; National Institute of Neurological Disorders and Stroke (NINDS); FusionHealth LLC; Medical University of South Carolina; University of Cincinnati Active, not recruiting
- Conditions: Alzheimer Disease Interventions: Drug: Lemborexant 10 mg; Drug: Lemborexant 20mg; Drug: Placebo Sponsors: Washington University School of Medicine; National Institutes of Health (NIH); Eisai Inc.; National Institute on Aging (NIA) Recruiting
- Conditions: Treatment Resistant Depression Interventions: Diagnostic Test: Electroencephalography (EEG); Diagnostic Test: Quantitative Measurements of Sleep Microstructure Sponsors: Washington University School of Medicine; National Institute of Mental Health (NIMH) Recruiting
- Conditions: Postoperative Delirium Sponsors: Washington University School of Medicine Completed
- Conditions: Intracranial Arteriosclerosis; Stroke Interventions: Drug: Ticagrelor + Aspirin; Drug: Rivaroxaban + Aspirin; Drug: Clopidogrel + Aspirin; Other: Risk Factor Management Sponsors: University of Florida; National Institute of Neurological Disorders and Stroke (NINDS); University of Cincinnati; Medical University of South Carolina; Janssen Scientific Affairs, LLC; AstraZeneca Recruiting
- Conditions: Acute Ischemic Stroke Interventions: Drug: BB-031; Drug: Placebo Sponsors: Basking Biosciences, Inc. Recruiting
- Conditions: Ischemic Stroke; Sleep Apnea; Sleep Apnea, Obstructive; Stroke; CPAP; Telemedicine; Home Sleep Apnea Test; Randomized Clinical Trial; Multicenter Trial Interventions: Device: CPAP Sponsors: University of Michigan; National Institute of Neurological Disorders and Stroke (NINDS); FusionHealth LLC; Medical University of South Carolina; University of Cincinnati Active, not recruiting
- Conditions: Hypoxia-Ischemia, Brain Interventions: Device: taVNS Sponsors: Washington University School of Medicine Enrolling by invitation
- Conditions: Stroke; Thromboses, Intracranial; Aneurysm, Brain Interventions: Procedure: Stroke/Thrombectomy/Aneurysm-specific surgical procedures Sponsors: Medical University of South Carolina Recruiting
- Conditions: Ischemic Stroke Interventions: Biological: TS23 Sponsors: Translational Sciences, Inc.; University of Cincinnati; National Institute of Neurological Disorders and Stroke (NINDS); Medical University of South Carolina; University of Arizona Recruiting
- Conditions: Subdural Hematoma Interventions: Procedure: Surgical Management; Device: Onyx™ Liquid Embolic System (LES) Embolization; Other: Observation Only; Device: Onyx™ Liquid Embolic System (LES) Embolization; Procedure: Surgical Management Sponsors: Medtronic Neurovascular Clinical Affairs Completed
- Conditions: Ischemic Stroke Interventions: Device: Endovascular thrombectomy with any FDA-approved category POL or NRY device; Other: Medical Management Sponsors: Medical University of South Carolina; National Institute of Neurological Disorders and Stroke (NINDS); University of Cincinnati; University of Virginia; Berry Consultants; University of California, Los Angeles; MOUNT SINAI HOSPITAL; The Cooper Health System; University of Pittsburgh Medical Center; Stony Brook University; University at Buffalo Recruiting
- Conditions: Cardiac Arrest, Out-Of-Hospital; Hypothermia, Induced; Hypoxia-Ischemia, Brain Interventions: Device: Therapeutic Hypothermia Sponsors: University of Michigan; National Heart, Lung, and Blood Institute (NHLBI); Kennedy Krieger Institute, Baltimore, MD Recruiting
- Conditions: Stroke Interventions: Behavioral: COMPASS; Behavioral: Education Program Sponsors: Washington University School of Medicine; Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Recruiting
- Conditions: Prevention of Ischemic Stroke; Acute Non-cardioembolic Ischemic Stroke; High-risk Transient Ischemic Attack Interventions: Drug: Asundexian (BAY2433334); Drug: Placebo Sponsors: Bayer Completed
- Conditions: Intracerebral Hemorrhage Interventions: Biological: Recombinant Factor VIIa; Biological: Biological/Vaccine: Placebo Sponsors: Joseph Broderick, MD; National Institute of Neurological Disorders and Stroke (NINDS); Japan Agency for Medical Research and Development; Novo Nordisk A/S Recruiting
- Conditions: Acute Ischemic Stroke Interventions: Device: transcutaneous auricular vagal nerve stimulation; Device: Sham transcutaneous vagal nerve stimulation Sponsors: Washington University School of Medicine Completed
- Conditions: Lupus Nephritis; Immunoglobulin A Nephropathy; Membranous Nephropathy; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis Interventions: Drug: Povetacicept Sponsors: Alpine Immune Sciences, Inc. Active, not recruiting
- Conditions: Intracerebral Hemorrhage Interventions: Drug: Statins Sponsors: Beth Israel Deaconess Medical Center; NINDS Stroke Trials Network (StrokeNet); Canadian Stroke Consortium (CSC); University of Cincinnati; Medical University of South Carolina; Yale University; MetroHealth Medical Center; UH, Cleveland Medical Center; Corewell Health West; West Virginia University; Columbia University; Weill Medical College of Cornell University; New York Presbyterian Brooklyn Methodist Hospital; Buffalo General Medical Center; State University of New York – Upstate Medical University; St. Joseph's Regional Medical Center, New Jersey; Tufts Medical Center; Massachusetts General Hospital; UMass Memorial Health; Brigham and Women's Hospital; Baystate Medical Center; University of Vermont Medical Center; Lahey […]
- Conditions: Stroke; Intracranial Atherosclerotic Stenosis (ICAS) Interventions: Other: MRI Sponsors: Yale University; National Institute of Neurological Disorders and Stroke (NINDS) Recruiting
- Conditions: Intracerebral Hemorrhage; Atrial Fibrillation Interventions: Drug: Apixaban; Drug: Aspirin Sponsors: Yale University; National Institute of Neurological Disorders and Stroke (NINDS) Recruiting
- Conditions: Intra Cerebral Hemorrhage; ICH – Intracerebral Hemorrhage; ICH; Hemorrhage; Stroke; Clot (Blood); Brain; Clot Blood; Cognitive Decline; Cognitive Impairment; Survivorship; Memory Impairment; Motor Activity Sponsors: Johns Hopkins University; National Institute of Neurological Disorders and Stroke (NINDS); National Institute on Aging (NIA) Enrolling by invitation
- Conditions: Intracerebral Hemorrhage Interventions: Biological: Recombinant Activated Factor VII (rFVIIa); Biological: Placebo Sponsors: Joseph Broderick, MD; Novo Nordisk A/S; National Institute of Neurological Disorders and Stroke (NINDS) Recruiting
- Conditions: Cerebral Stroke Interventions: Device: EmboTrap® Revascularization Device; Device: CERENOVUS Large Bore Catheter/ EMBOVAC Aspiration Catheter; Device: CEREGLIDE 71 Intermediate Catheter Sponsors: Cerenovus, Part of DePuy Synthes Products, Inc. Completed
A patient’s story
Seeking a cure for future ALS patients — “I care, and I want to help.”